Phentermine And Topiramate
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
VIVUS · Phase 3 · Completed · Enrollment 756
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
- VI-0521 Top
- VI-0521 Mid
- TPM 46
- TPM 92
- PHEN 7.5
- PHEN 15
- Placebo
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| VI-0521 Top | 66% | n/r | n/r | n/r |
| VI-0521 Mid | 62.1% | n/r | n/r | n/r |
| TPM 46 | 39.2% | n/r | n/r | n/r |
| TPM 92 | 48.6% | n/r | n/r | n/r |
| PHEN 7.5 | 43.3% | n/r | n/r | n/r |
| PHEN 15 | 46.2% | n/r | n/r | n/r |
| Placebo | 15.5% | n/r | n/r | n/r |
Not shown
Every selected arm is drawn.